| A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010) (NCT06626464) | Merck Sharp & Dohme LLC | 2022-05-13 |
| Activity Tracking Study in Healthy Volunteers (MK-0000-419) (NCT06833879) | Merck Sharp & Dohme LLC | 2022-05-12 |
| Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) (NCT05314023) | Merck Sharp & Dohme LLC | 2022-05-07 |
| Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) (NCT05298423) | Merck Sharp & Dohme LLC | 2022-05-03 |
| Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) (NCT05136690) | Merck Sharp & Dohme LLC | 2022-04-27 |
| Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (NCT05239741) | Merck Sharp & Dohme LLC | 2022-04-02 |
| Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076) (NCT05119855) | Merck Sharp & Dohme LLC | 2022-03-28 |
| Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016) (NCT05289271) | Merck Sharp & Dohme LLC | 2022-03-25 |
| Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (NCT05226598) | Merck Sharp & Dohme LLC | 2022-03-24 |
| Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) (NCT05224141) | Merck Sharp & Dohme LLC | 2022-03-24 |
| A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) (NCT06733688) | Merck Sharp & Dohme LLC | 2022-03-23 |
| A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) (NCT05239728) | Merck Sharp & Dohme LLC | 2022-03-15 |
| A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008) (NCT05261126) | Merck Sharp & Dohme LLC | 2022-03-10 |
| Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) (NCT05173987) | Merck Sharp & Dohme LLC | 2022-02-03 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (NCT05139017) | Merck Sharp & Dohme LLC | 2022-01-14 |
| Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (NCT05158140) | Merck Sharp & Dohme LLC | 2022-01-12 |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283) | Merck Sharp & Dohme LLC | 2021-12-17 |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). (NCT05116189) | Merck Sharp & Dohme LLC | 2021-12-13 |
| Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) (NCT04938830) | Merck Sharp & Dohme LLC | 2021-11-30 |
| A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) (NCT04980872) | Merck Sharp & Dohme LLC | 2021-11-02 |
| A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (NCT05093933) | Merck Sharp & Dohme LLC | 2021-11-02 |
| A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) (NCT04924114) | Merck Sharp & Dohme LLC | 2021-10-14 |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) (NCT05030506) | Merck Sharp & Dohme LLC | 2021-10-13 |
| Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (NCT05008224) | Merck Sharp & Dohme LLC | 2021-10-07 |
| A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) (NCT05005442) | Merck Sharp & Dohme LLC | 2021-09-28 |
| A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) (NCT05038800) | Merck Sharp & Dohme LLC | 2021-09-26 |
| A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (NCT05017012) | Merck Sharp & Dohme LLC | 2021-09-21 |
| Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033) (NCT04776252) | Merck Sharp & Dohme LLC | 2021-09-15 |
| Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) (NCT04938817) | Merck Sharp & Dohme LLC | 2021-08-19 |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (NCT04976634) | Merck Sharp & Dohme LLC | 2021-08-18 |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) (NCT04924075) | Merck Sharp & Dohme LLC | 2021-08-12 |
| Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) (NCT04939428) | Merck Sharp & Dohme LLC | 2021-08-11 |
| Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) (NCT04956692) | Merck Sharp & Dohme LLC | 2021-08-05 |
| A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) (NCT04944992) | Merck Sharp & Dohme LLC | 2021-08-04 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (NCT04949256) | Merck Sharp & Dohme LLC | 2021-07-28 |
| Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) (NCT04924101) | Merck Sharp & Dohme LLC | 2021-07-15 |
| Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). (NCT04895722) | Merck Sharp & Dohme LLC | 2021-06-25 |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) (NCT04846920) | Merck Sharp & Dohme LLC | 2021-06-14 |
| A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) (NCT04875195) | Merck Sharp & Dohme LLC | 2021-06-07 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension (NCT04934722) | Merck Sharp & Dohme LLC | 2021-05-25 |
| Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) (NCT04663321) | Merck Sharp & Dohme LLC | 2021-05-20 |
| A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) (NCT04732221) | Merck Sharp & Dohme LLC | 2021-05-19 |
| Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066) (NCT04772534) | Merck Sharp & Dohme LLC | 2021-05-17 |
| A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (NCT07218029) | Merck Sharp & Dohme LLC | 2021-05-12 |
| Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) (NCT04700072) | Merck Sharp & Dohme LLC | 2021-05-03 |
| Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (NCT04700124) | Merck Sharp & Dohme LLC | 2021-04-21 |
| Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) (NCT04725188) | Merck Sharp & Dohme LLC | 2021-04-20 |
| A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) (NCT04736706) | Merck Sharp & Dohme LLC | 2021-04-14 |
| Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) (NCT04738487) | Merck Sharp & Dohme LLC | 2021-04-07 |
| Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) (NCT04767373) | Merck Sharp & Dohme LLC | 2021-04-07 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (NCT04728893) | Merck Sharp & Dohme LLC | 2021-04-05 |
| Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (NCT04776148) | Merck Sharp & Dohme LLC | 2021-03-29 |
| Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) (NCT04730635) | Merck Sharp & Dohme LLC | 2021-03-23 |
| A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012) (NCT04676425) | Merck Sharp & Dohme LLC | 2021-03-17 |
| Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) (NCT04740307) | Merck Sharp & Dohme LLC | 2021-03-16 |
| Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (NCT04652700) | Merck Sharp & Dohme LLC | 2021-03-15 |
| Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069) (NCT04708041) | Merck Sharp & Dohme LLC | 2021-03-15 |
| A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (NCT04586231) | Merck Sharp & Dohme LLC | 2021-02-25 |
| Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (NCT04644029) | Merck Sharp & Dohme LLC | 2021-02-24 |
| Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (NCT04704219) | Merck Sharp & Dohme LLC | 2021-02-23 |
| MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005) (NCT04308304) | Merck Sharp & Dohme LLC | 2021-02-16 |
| Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004) (NCT04678505) | Merck Sharp & Dohme LLC | 2021-02-10 |
| Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) (NCT04633226) | Merck Sharp & Dohme LLC | 2021-02-10 |
| Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) (NCT04665050) | Merck Sharp & Dohme LLC | 2021-02-04 |
| Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (NCT04375800) | Merck Sharp & Dohme LLC | 2021-02-03 |
| Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) (NCT04634877) | Merck Sharp & Dohme LLC | 2021-01-10 |
| Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (NCT04662710) | Merck Sharp & Dohme LLC | 2020-12-30 |
| Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) (NCT04626518) | Merck Sharp & Dohme LLC | 2020-12-17 |
| Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (NCT04626479) | Merck Sharp & Dohme LLC | 2020-12-16 |
| Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (NCT04624243) | Merck Sharp & Dohme LLC | 2020-12-15 |
| Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) (NCT04624204) | Merck Sharp & Dohme LLC | 2020-12-08 |
| Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) (NCT04635423) | Merck Sharp & Dohme LLC | 2020-11-30 |
| Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028) (NCT04295772) | Merck Sharp & Dohme LLC | 2020-11-26 |
| A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) (NCT04583423) | Merck Sharp & Dohme LLC | 2020-11-11 |
| Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) (NCT04515641) | Merck Sharp & Dohme LLC | 2020-11-05 |
| A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (NCT05523323) | Merck Sharp & Dohme LLC | 2020-10-30 |
| Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001) (NCT04569786) | Merck Sharp & Dohme LLC | 2020-10-29 |
| A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) (NCT04521621) | Merck Sharp & Dohme LLC | 2020-10-28 |
| A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) (NCT04489888) | Merck Sharp & Dohme LLC | 2020-10-27 |
| Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085) (NCT04571944) | Merck Sharp & Dohme LLC | 2020-10-22 |
| Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002) (NCT04575597) | Merck Sharp & Dohme LLC | 2020-10-19 |
| Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001) (NCT04575584) | Merck Sharp & Dohme LLC | 2020-10-19 |
| Islatravir and Methadone Pharmacokinetics (MK-8591-029) (NCT04568603) | Merck Sharp & Dohme LLC | 2020-10-16 |
| Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension (NCT04907227) | Merck Sharp & Dohme LLC | 2020-09-23 |
| A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) (NCT04489771) | Merck Sharp & Dohme LLC | 2020-09-13 |
| V114 and Acute Otitis Media (V114-032/PNEU-ERA) (NCT04193215) | Merck Sharp & Dohme LLC | 2020-09-12 |
| A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013) (NCT04490499) | Merck Sharp & Dohme LLC | 2020-09-02 |
| Gluten Challenge Study in Celiac Disease Participants (MK-0000-402) (NCT04054544) | Merck Sharp & Dohme LLC | 2020-08-28 |
| Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011) (NCT04506905) | Merck Sharp & Dohme LLC | 2020-08-28 |
| A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001) (NCT04498247) | Merck Sharp & Dohme LLC | 2020-08-27 |
| Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074) (NCT04481191) | Merck Sharp & Dohme LLC | 2020-08-25 |
| Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) (NCT04456699) | Merck Sharp & Dohme LLC | 2020-08-19 |
| Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (NCT04428151) | Merck Sharp & Dohme LLC | 2020-08-06 |
| A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (NCT04447755) | Merck Sharp & Dohme LLC | 2020-07-30 |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (NCT04882241) | Merck Sharp & Dohme LLC | 2020-07-29 |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study (NCT04889118) | Merck Sharp & Dohme LLC | 2020-07-14 |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study (NCT04924062) | Merck Sharp & Dohme LLC | 2020-07-10 |
| Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) (NCT04425733) | Merck Sharp & Dohme LLC | 2020-07-07 |
| Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (NCT04380636) | Merck Sharp & Dohme LLC | 2020-07-06 |
| Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) (NCT04218851) | Merck Sharp & Dohme LLC | 2020-07-02 |